These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 2275640)

  • 1. Changes of stapedius reflex and hearing threshold in patients receiving high-dose cisplatin treatment.
    Laurell G; Skedinger M
    Audiology; 1990; 29(5):252-61. PubMed ID: 2275640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evoked otoacoustic emissions--an approach for monitoring cisplatin induced ototoxicity in children.
    Stavroulaki P; Apostolopoulos N; Segas J; Tsakanikos M; Adamopoulos G
    Int J Pediatr Otorhinolaryngol; 2001 May; 59(1):47-57. PubMed ID: 11376818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Stapedius reflex. 1. Stapedius reflex threshold and recruitment].
    Wurzer H
    Laryngol Rhinol Otol (Stuttg); 1983 Jul; 62(7):289-92. PubMed ID: 6621210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The utility of acoustic reflex thresholds and other conventional audiologic tests for monitoring cisplatin ototoxicity in the pediatric population.
    Park KR
    Ear Hear; 1996 Apr; 17(2):107-15. PubMed ID: 8698156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
    Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D
    Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and validation of a cisplatin dose-ototoxicity model.
    Dille MF; Wilmington D; McMillan GP; Helt W; Fausti SA; Konrad-Martin D
    J Am Acad Audiol; 2012; 23(7):510-21. PubMed ID: 22992258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ototoxic effects of supradose cisplatin with sodium thiosulfate neutralization in patients with head and neck cancer.
    Madasu R; Ruckenstein MJ; Leake F; Steere E; Robbins KT
    Arch Otolaryngol Head Neck Surg; 1997 Sep; 123(9):978-81. PubMed ID: 9305250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evoked otoacoustic emissions and pure tone threshold audiometry in patients receiving cisplatinum therapy.
    Zorowka PG; Schmitt HJ; Gutjahr P
    Int J Pediatr Otorhinolaryngol; 1993 Jan; 25(1-3):73-80. PubMed ID: 8436482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The importance of high-tone audiometry in monitoring for ototoxicity.
    Tange RA; Dreschler WA; van der Hulst RJ
    Arch Otorhinolaryngol; 1985; 242(1):77-81. PubMed ID: 3899068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of high-frequency audiometry in early detection of ototoxicity.
    Dreschler WA; vd Hulst RJ; Tange RA; Urbanus NA
    Audiology; 1985; 24(6):387-95. PubMed ID: 4084111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of quinine on psychoacoustic tuning curves, stapedius reflexes and evoked otoacoustic emissions in healthy volunteers.
    Karlsson KK; Berninger E; Alván G
    Scand Audiol; 1991; 20(2):83-90. PubMed ID: 1842280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABR evaluation of ototoxicity in cancer patients receiving cisplatin or carboplatin.
    De Lauretis A; De Capua B; Barbieri MT; Bellussi L; Passàli D
    Scand Audiol; 1999; 28(3):139-43. PubMed ID: 10489862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of transient evoked otoacoustic emissions to detect and monitor cochlear damage caused by platinum-containing drugs.
    Yardley MP; Davies CM; Stevens JC
    Br J Audiol; 1998 Oct; 32(5):305-16. PubMed ID: 9845029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Audiometric patterns in ototoxicity of intra-arterial Cisplatin chemoradiation in patients with locally advanced head and neck cancer.
    Zuur CL; Simis YJ; Lansdaal PE; Rasch CR; Tange RA; Balm AJ; Dreschler WA
    Audiol Neurootol; 2006; 11(5):318-30. PubMed ID: 16983183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of protective agents against cisplatin ototoxicity.
    Rybak LP; Husain K; Morris C; Whitworth C; Somani S
    Am J Otol; 2000 Jul; 21(4):513-20. PubMed ID: 10912697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-frequency pure-tone audiometry in children: a test-retest reliability study relative to ototoxic criteria.
    Beahan N; Kei J; Driscoll C; Charles B; Khan A
    Ear Hear; 2012; 33(1):104-11. PubMed ID: 21760512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ototoxicity due to cis-diamminedichloroplatinum in the treatment of ovarian cancer: influence of dosage and schedule of administration.
    Waters GS; Ahmad M; Katsarkas A; Stanimir G; McKay J
    Ear Hear; 1991 Apr; 12(2):91-102. PubMed ID: 2065844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progression of hearing loss following the completion of chemotherapy and radiation therapy: case report.
    Sweetow RW; Will TI
    J Am Acad Audiol; 1993 Nov; 4(6):360-3. PubMed ID: 8298170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Stapedius-reflex-audiometry by measuring the threshold for the re-inforcement of a pre-existing reflex (author's transl)].
    Reker U; Baumgarten D
    Laryngol Rhinol Otol (Stuttg); 1980 Sep; 59(9):557-61. PubMed ID: 7464371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cisplatin ototoxicity. A clinical study].
    Schröder M; Laskawi R; Stennert E; Kühnle H; Thiele FW
    Laryngol Rhinol Otol (Stuttg); 1986 Feb; 65(2):86-9. PubMed ID: 3959692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.